{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:43:33Z","timestamp":1789746213529,"version":"4.0.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Treatment with a combination of immune checkpoint inhibitors (ICIs) (pembrolizumab or nivolumab) and oral Tyrosine Kinase Inhibitors (TKI) targeting angiogenesis (axitinib, cabozantinib or lenvatinib) has shown benefits in terms of efficacy and survival in metastatic renal cell carcinoma (mRCC), with a favorable toxicity profile. However, some rare and serious treatment-related adverse events can be difficult to manage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Here we report the first case of an mRCC patient who, after only 2 administrations of pembrolizumab-axitinib, experienced severe multiorgan failure (MOF) with heart failure, oliguria and acute hepatitis requiring aggressive supportive treatment in intensive care unit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>A diagnosis of severe MOF induced by pembrolizumab plus axitinib was considered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with dobutamine, levosimendan along with high-dose steroids under continuous cardiologic monitoring.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After treatment, the patient had a full recovery and was discharged from the hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We reviewed all the other cases of MOF reported during treatment with combined ICI-TKI in cancer patients in order to summarize incidence, clinical manifestations and management with a specific focus on the need for prompt recognition and aggressive management under multidisciplinary care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037606","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T18:02:09Z","timestamp":1711735329000},"page":"e37606","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-9022","authenticated-orcid":false,"given":"Andrea","family":"Di Marco","sequence":"first","affiliation":[{"name":"Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Artioli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AULSS 2 Marca Trevigiana, Ca\u2019 Foncello Hospital, Treviso, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Favaretto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AULSS 2 Marca Trevigiana, Ca\u2019 Foncello Hospital, Treviso, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Cavasin","sequence":"additional","affiliation":[{"name":"Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy"},{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[{"name":"Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis.","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"k793","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","article-title":"Axitinib: a review in advanced renal cell carcinoma.","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JU.0000000000002252","article-title":"Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis.","volume":"207","author":"Nocera","year":"2022","journal-title":"J Urol"},{"key":"R11-20250503","first-page":"273","article-title":"Multiple organ dysfunction syndrome.","volume":"43","author":"Ram\u00edrez","year":"2013","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nri2402","article-title":"Harmful molecular mechanisms in sepsis.","volume":"8","author":"Rittirsch","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.","volume":"123","author":"Gr\u00fcnwald","year":"2020","journal-title":"Br J Cancer"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.cllc.2019.10.008","article-title":"Fatal simultaneous multi-organ failure following pembrolizumab treatment for refractory thymoma.","volume":"21","author":"Hyun","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"569466","DOI":"10.3389\/fphar.2020.569466","article-title":"Case report: fatal multiorgan failure and heterochronous pneumonitis following pembrolizumab treatment in a patient with large-cell neuroendocrine carcinoma of lung.","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors.","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1536\/ihj.20-162","article-title":"A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma.","volume":"61","author":"Matsui","year":"2020","journal-title":"Int Heart J"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis.","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade.","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","article-title":"Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study.","volume":"16","author":"Goldman","year":"2021","journal-title":"Target Oncol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0707778105","article-title":"Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation.","volume":"105","author":"May","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMc1108849","article-title":"Reversible cardiomyopathy associated with sunitinib and sorafenib.","volume":"365","author":"Uraizee","year":"2011","journal-title":"N Engl J Med"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1536\/ihj.21-307","article-title":"Vascular endothelial growth factor receptor inhibitors impair left ventricular diastolic functions.","volume":"62","author":"Yokoyama","year":"2021","journal-title":"Int Heart J"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1177\/1078155220909422","article-title":"Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma.","volume":"26","author":"Tanriverdi","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.euo.2021.05.007","article-title":"Characterization and management of treatment-emergent hepatic toxicity in patients with advanced renal cell carcinoma receiving first-line pembrolizumab plus axitinib. Results from the KEYNOTE-426 trial.","volume":"5","author":"Rini","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ijgc-2022-003532","article-title":"Acute heart failure during lenvatinib plus pembrolizumab therapy.","volume":"32","author":"Nakazawa","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"174","DOI":"10.14694\/EdBook_AM.2012.32.79","article-title":"Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist.","volume":"32","author":"Weber","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study.","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"103579","DOI":"10.1016\/j.critrevonc.2022.103579","article-title":"Immune checkpoint inhibitors rechallenge in urological tumors: an extensive review of the literature.","volume":"170","author":"Bimbatti","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:02:32Z","timestamp":1746313352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037606","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}